3 Long-term Income Plays: Legal And General Group Plc, GlaxoSmithKline Plc And SSE PLC

Legal & General Group Plc (LON: LGEN), GlaxoSmithKline Plc (LON: GSK) and SSE PLC (LON: SSE) will bring joy to long-term income seekers, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Share price growth can give investors a real buzz in the short-term, but it’s the dividend income that brings the most satisfying long-term rewards. If you can generate 4% or 5% a year and use that to buy more shares in the same company, eventually you will be talking real money.

Up to three-quarters of your long-term returns will come from dividend income. The key phrase here is long-term. Here are three income stocks with staying power.

Legal & General Group

Over the last five years, FTSE-listed insurance giant Legal & General Group (LSE: LGEN) has doubled your money in share price growth alone. The last year has been stickier with the stock down 15%, but that won’t worry long-term income seekers, as L&G currently yields 5.62%. In fact, it works in their favour, because if they re-invest their dividends they’ll pick up more stock at the lower price.

Somebody who invested five years ago, when the stock traded at 116p (against 238p today), is effectively getting a yield of 11.5% on their original investment. FTSE insurers have all been hit by wider stock market uncertainty yet L&G still has plenty in its favour, as a major presence in three fast-growing areas: low-cost tracker funds, UK workplace auto-enrolment schemes and bulk annuities. Earnings per share (EPS) are forecast to rise 7% this year and 8% in 2016, when the yield is expected to hit an even juicier 6.4%.

GlaxoSmithKline

Investment fashions change but one thing seems eternal: pharmaceutical giant GlaxoSmithKline (LON: GSK) is still the FTSE 100 poster boy for dividend income. Yet even dividend heroes can suffer their moments of misfortune, with the Chinese bribery scandal and more importantly, fears of a patent cliff, hitting investor sentiment. Glaxo has been trying to wean itself off its dependence on respiratory treatment Advair/Seretide, with sales down sharply on generic competition. Moves to diversify into vaccines and consumer health, pharmaceutical products and the HIV franchise, are finally bearing fruit.

Four years of negative EPS are expected to turn positive with a vengeance in 2016, rising 14%. Forecast dividend growth looks less spectacular, but the yield is expected to continue hovering around 5.4%, perfect for investors who like to play the long game.

SSE

Some may think I’m rash by including utility company SSE (LSE: SSE) under the heading “long-term income plays”. Its dividend may yield a juicy 5.83% but there has been talk of a cut as cover gets stretched. SSE has been hit by falling energy prices and increased retail market competition, as disgruntled customers switch from the Big Six energy companies to smaller challengers.

Management has committed to raising its dividend by RPI inflation at least, a commitment it stands by even though EPS are expected to fall from 124.1p in the year to March 2015 to 111.79p this year, a drop of almost 10%. It also warned that dividend cover could range from around 1.2 times to around 1.4 times over the next three years, but the yield is still forecast to hit 6% by March 2018, suggesting fears of a cut are overplayed. It still has its believers: JP Morgan is overweight with a target price of 1,550p, only slightly above today’s 1,515p. That confirms my view: forget growth, SSE is all about the income, and the income is good.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Can someone invest like Warren Buffett with a spare £500?

Christopher Ruane explains why an investor without the resources of billionaire Warren Buffett could still learn from his stock market…

Read more »

Investing Articles

Can these 2 incredible FTSE 250 dividend stocks fly even higher in 2026?

Mark Hartley examines the potential in two FTSE 250 shares that have had an excellent year and considers what 2026…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Is 45 too late to start investing?

Investing at different life stages can come with its own challenges -- and rewards. Our writer considers why a 45-year-old…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

UK shares look cheap — but the market might be about to take notice

UK shares have traded at a persistent discount to their US counterparts. This can create huge opportunities, but investors need…

Read more »

Investing Articles

This FTSE 100 growth machine is showing positive signs for a 2026 recovery

FTSE 100 distributor Bunzl is already the second-largest holding in Stephen Wright’s Stocks and Shares ISA. What should his next…

Read more »

Investing Articles

I asked ChatGPT for the best FTSE 100 stocks to buy for passive income in 2026 and it said…

Paul Summers wanted to learn which dividend stocks an AI bot thinks might be worth buying for 2026. Its response…

Read more »

ISA Individual Savings Account
Investing Articles

Stop missing out! A Stocks and Shares ISA could help you retire early

Investors who don't use a Stocks and Shares ISA get all the risks that come with investing but with less…

Read more »

Investing Articles

Will Greggs shares crash again in 2026?

After a horrible 2025, Paul Summers takes a look at whether Greggs shares could sink even further in price next…

Read more »